Pay in 4 interest-free payments of $6.65 Learn more
Ships within 48 hours · Estimated delivery Aug 14 - Aug 19
Mod GRF(129)
Before discontinuing use of a prescribed incretin receptor agonist, there are alternatives that may help maintain a more stable weight
HOMA-IR, a calculated measure of insulin resistance derived from fasting glucose and insulin, provides a single number to track over time
Type 2 diabetes management Improving HbA1c levels Supporting blood glucose control Used when diet and exercise alone are insufficient Alternative to injectable GLP-1 medications (where clinically appropriate) Rybelsus is not indicated for type 1 diabetes
Advertisement Kristin Louden: That they're not safe or that they're a shortcut
The synergistic effect of activating all three receptors simultaneously promotes significant weight loss and better metabolic control than other existing GLP-1 receptor agonists, such as semaglutide (Wegovy and Ozempic), liraglutide, dulaglutide, and dual-agonists like tirzepatide (Mounjaro and Zepbound)
US$ 24.03
US$ 22.15
US$ 21.73
US$ 23.55
US$ 20.06
US$ 23.98
US$ 28.23
